Layered immunohistochemistry (L-IHC) is an important new, patented technology for profiling multiple biomarkers in tumors to help personalize cancer therapies.  Co-developed by 20/20 GeneSystems, Inc. (Rockville, MD) and a team from the National Cancer Instititue’s Laboratory of Pathology,  L-IHC permits the analysis of entire cell signaling pathways to help determine patient response to molecular-targeted therapies and to determine disease prognosis. For an overview of the technology, please view the animation [here]

We are now using L-IHC to develop diagnostic tests to predict tumor response to FDA approved targeted therapies.  Our first anticipated product–PredicTOR™–will help predict tumor response drugs that target the mTOR pathway including Torisel® and Afinitor®.